Healthcare disparities in cardio oncology: patients receive same level of surveillance regardless of race at a safety net hospital

Table 6 Multivariate analysis of variables associated with increased referral rate of patients receiving cardiotoxic chemotherapy from oncology clinic to cardio-oncology or cardiology clinic

	Odds Ratio	Confidence Interval	P-value
Race
Black	Reference
White	1.47	0.50–4.32	p = 0.48
Hispanic	1.34	0.43–4.19	p = 0.62
Other	0.42	0.05–3.74	p = 0.43
Age	0.96	0.93–1.00	p = 0.08
Gender
Male	Reference
Female	0.20	0.03–1.33	p = 0.10
Insurance
Private	Reference
Medicare	0.48	0.13–1.84	p = 0.29
Medicaid	0.69	0.08–5.77	p = 0.74
Self	0.23	0.03–1.57	p = 0.13
Income by ZIP code*
Quartile 1	Reference
Quartile 2	3.61	0.95–13.67	p = 0.06
Quartile 3	5.35	1.35–21.26	p = 0.017
Quartile 4	4.38	1.00–19.13	p = 0.049
Risk factors
HTN	6.85	2.68–17.52	p = 0.0001
HLD	1.07	0.41–2.81	p = 0.90
CAD	0.15	0.01–1.63	p = 0.12
Arrhythmia	1.82	0.35–9.52	p = 0.48
DM	1.78	0.67–4.75	p = 0.25
Smoking	1.18	0.47–2.99	p = 0.73
FH	0.79	0.29–2.13	p = 0.64
Age > 65	4.01	0.10–16.17	p = 0.051
Cancer type
Breast cancer	Reference
Other cancer^	0.12	0.02–0.74	p = 0.02
Cancer stage
Stage 1	Reference
Stage 2	0.31	0.05–1.83	p = 0.20
Stage 3	0.16	0.02–1.33	p = 0.09
Stage 4	0.23	0.03–1.78	p = 0.16
Chemotherapy
Doxorubicin	1.49	0.34–6.53	p = 0.60
Herceptin	0.70	0.12–3.97	p = 0.68
Medications pre-chemotherapy
BB	2.04	0.46–9.06	p = 0.35
ACEI/ARB	0.16	0.04–0.70	p = 0.01
Diuretic	2.31	0.24–22.47	p = 0.47
CCB	1.28	0.28–5.91	p = 0.75
ASA	2.28	0.42–12.49	p = 0.34
Statin	0.66	0.12–3.63	p = 0.63

ISSN: 2057-3804